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ABSTRACT
Background Effective interventions are available to
reduce cardiovascular risk. Recently, health check
programmes have been implemented to target those at
high risk of cardiovascular disease (CVD), but there is
much debate whether these are likely to be effective at
population level. This paper evaluates the impact of
wave 1 of Keep Well, a Scottish health check
programme, on cardiovascular outcomes.
Methods Interrupted time series analyses were
employed, comparing trends in outcomes in participating
and non-participating practices before and after the
introduction of health checks. Health outcomes are
deﬁned as CVD mortality, incident hospitalisations and
prescribing of cardiovascular drugs.
Results After accounting for secular trends and
seasonal variation, coronary heart disease mortality and
hospitalisations changed by 0.4% (95% CI −5.2% to
6.3%) and −1.1% (−3.4% to 1.3%) in Keep Well
practices and by −0.3% (−2.7% to 2.2%) and −0.1%
(−1.8% to 1.7%) in non-Keep Well practices,
respectively, following the intervention. Adjusted changes
in prescribing in Keep Well and non-Keep Well practices
were 0.4% (−10.4% to 12.5%) and −1.5% (−9.4% to
7.2%) for statins; −2.5% (−12.3% to 8.4%) and
−1.6% (−7.1% to 4.3%) for antihypertensive drugs;
and −0.9% (−6.5% to 5.0%) and −2.4% (−10.1% to
6.0%) for antiplatelet drugs.
Conclusions Any impact of the Keep Well health
check intervention on CVD outcomes and prescribing in
Scotland was very small. Findings do not support the
use of the screening approach used by current health
check programmes to address CVD. We used an
interrupted time series method, but evaluation methods
based on randomisation are feasible and preferable and
would have allowed more reliable conclusions. These
should be considered more often by policymakers at an
early stage in programme design when there is
uncertainty regarding programme effectiveness.
INTRODUCTION
Cardiovascular disease (CVD) is a major cause of
death and an important contributor to the wide
and growing inequalities in mortality in high-
income countries.1 As a result, the reduction of
CVD has long been an objective of health policy in
the UK and elsewhere, with a series of initiatives
introduced with this as either a primary or second-
ary focus.2
Recently, there has been interest in the potential
of ‘health checks’ (a non-programmatic form of
screening for CVD risk factors) to contribute to
reductions in overall CVD mortality and inequal-
ities.3 4 The core theory for this approach is that it
is possible to inﬂuence several of the factors (such
as smoking, high blood pressure and obesity) that
increase the risk of CVD, using primary prevention
therapies such as statin and antihypertensive drugs
and behavioural interventions to reduce CVD risk
for those without CVD but currently at high risk.
By systematically identifying and offering treatment
to those at high risk, it is proposed that population
health improvement (and reductions in health
inequality) can be expected.3 However, there is con-
troversy about whether health check programmes
are effective in reducing the CVD risk of popula-
tions5 6 and whether an approach based on identify-
ing individuals at high risk is appropriate.7–9
Keep Well (KW) was originally funded by the
Scottish Government as a CVD prevention pro-
gramme based on health checks in primary care.10
It was primarily designed to reduce CVD incidence
and to narrow socioeconomic inequalities in
CVD.11 Previous evaluation work focused on
implementation and reach of the programme, but
questions surrounding the impact on health
impacts could not be addressed.12 We aimed to
assess whether trends in CVD-related mortality,
hospitalisations and prescribing in those general
practices involved in wave 1 of the KW programme
changed after the implementation of the pro-
gramme and whether they differed from the trends
in non-KW practices. We used an interrupted time
series design as the best available means of assessing
its impact. The programme’s prespeciﬁed theory of
change indicated that, if successful, there would be
increased prescribing of preventive therapies for
CVD risk factors in the short-to-medium term, and
greater reductions in CVD hospitalisations and
mortality in the medium-to-long term in the KW
intervention practices compared with non-KW
practices.11
METHODS
The KW programme
The ‘wave 1’ KW model was introduced in 2006
using heath checks delivered in primary care for
adults aged 40–64 years living in areas of the great-
est material deprivation.11 Those eligible were
offered a CVD-focused health check to identify
modiﬁable risk factors (using the ASSIGN score13).
Those identiﬁed as having high CVD risk were
offered a combination of advice, medical therapy
and signposting or referral to other sources of
support, including smoking cessation and weight
loss programmes according to their identiﬁed risk
factors.11
In wave 1 of KW, implementation occurred in the
ﬁve Community Health Partnerships (CHPs) with
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the highest proportion of their population living in the most
deprived areas; deﬁned using the Scottish Index of Multiple
Deprivation (SIMD), which identiﬁes small area concentrations
of multiple deprivation across Scotland.14 The ﬁve pilot sites
were within four National Health Service (NHS) Health Boards
(NHS Greater Glasgow and Clyde (NHSGGC), NHS
Lanarkshire, NHS Lothian and NHS Tayside). By 2013/2014,
NHS Boards reported that a total of 251 734 health checks had
been carried out, of which 85.5% were delivered to individuals
residing in the two most deprived SIMD quintiles (SIMD
1=70.8%, SIMD 2=14.7%).11
Data sources and variables
For the period January 1999 to August 2013, we obtained
monthly counts of deaths and incident hospitalisations for
stroke and coronary heart disease (CHD) among those aged
40–65 years from the Information Services Division (ISD) of
NHS National Services Scotland for two groups of general prac-
tices: (1) those taking part in wave 1 of KW and (2) all other
Scottish practices. Incident cases were deﬁned as admissions or
deaths where there was no record of a hospitalisation for the
same diagnosis in the 10 years prior to the index event. For
each month, we obtained separate counts for KW wave 1
general practices and for all other Scottish practices. We used
corresponding population denominators for the KW and
non-KW populations to calculate mortality and hospitalisation
rates. CHD was deﬁned using International Classiﬁcation of
Diseases (ICD)9 codes 410-14 and ICD10 codes I20-25. Stroke
(broadly deﬁned as cerebrovascular disease) was deﬁned using
ICD9 codes 430-38 and ICD10 codes I60-69 and G45.
Prescribing data were obtained from ISD for the period
January 2002 to June 2011 for all general practices in Scotland.
We included prescriptions used in the primary prevention of
CVD, categorised into statins, antihypertensives and antiplatelet
drugs using classiﬁcations from the British National Formulary.
The data for each drug were provided as deﬁned daily doses
(DDDs) by general practice and month of prescription. Total
general practice populations for each practice and each year
were also provided by ISD from the Community Health Index
(CHI) database to serve as denominators. ISD were provided
with the date on which general practices started implementation
of KW checks to allow coding of the prescriptions data as pre-
implementation or postimplementation without disclosure of
the identity of individual practices. All data were provided at an
aggregate level and the analytical approach described below
reﬂects these data structure.
Analytical approach
Mortality and hospitalisations
We calculated monthly incidence rates for each health outcome
for the KW and non-KW practice groups. We modelled the KW
intervention effect using a covariate (St) coded as 0 at all time
points before the intervention had started (prior to October
2006) and coded as 1 at all time points after KW implementa-
tion (after August 2010). For time points between these dates,
the covariate took a value between 0 and 1, deﬁned as the sum
of the population size of practices that had started KW imple-
mentation at the given time point divided by the total popula-
tion size of all KW practices by August 2010. The intervention
covariate (St) was therefore the proportion of the population
size covered by KW at any given point in time as a fraction of
the ﬁnal KW population size. The interpretation of the expo-
nential of the coefﬁcient associated with St is a percentage
change in the level of outcome after KW was implemented in all
participating practices (from September 2010) compared with
before KW was implemented in any practice (prior to October
2006).
Mortality and hospitalisation rates were modelled using time
series regression with autoregressive integrated moving average
(ARIMA) errors4 (additional information in the online
supplementary material S1). Our analytical strategy consisted of
initially modelling the respective series without the intervention
to obtain an adequate preliminary model that passed all diag-
nostic tests and then modelling and testing the effect of the
intervention.15 The most appropriate and parsimonious model
was selected using the Akaike Information Criterion (AIC).16
Web-table 1 provides further speciﬁcations of these models.
To enable comparison with a control group, we employed the
same analytical approach using data for non-KW practices. In
addition, simultaneous time series of corresponding mortality
and hospitalisation rates in non-KW practices were entered as a
covariate in the ARIMA error models for KW practices. This
allowed us to control for factors external to the intervention
which might affect mortality and hospitalisation rates, providing
a ‘net effect’ of the intervention.17
Prescribing
Regression models were used to assess changes in prescribing
after the introduction of KW for practices implementing wave 1
of the programme and for non-KW practices. ARIMA error
models were created for each drug category to account for auto-
correlation and seasonality in the data.18 In further analyses, we
examined the possibility of a variation of the intervention effect
between different health boards by including interaction terms.
Data from 66 wave 1 KW practices were included for the add-
itional analyses (data from practices in NHS Tayside did not
include practice codes and could not be matched by ISD to the
practice-level data on prescription rates and so were excluded).
Generalised estimating equations (GEEs) were used to analyse
prescribing data over time for practices in the remaining three
health board areas. The quasi-likelihood under the independ-
ence model criterion (QIC) statistic informed model selection.19
All analyses were undertaken using Stata V.12.1 software (Stata
Corp, College Station, Texas, USA; http://www.stata.com).
Ethical approval was not sought since the study used aggregated
data.
RESULTS
Mortality and hospitalisations
Modelling results are presented in table 1. These show changes
relative to the preintervention period for KW and non-KW
practices. Rates of incident hospitalisation and mortality for
CHD and stroke in KW and non-KW practices are shown in
ﬁgure 1A–D. CHD mortality declined over time in KW and
non-KW practices, with KW practices having consistently higher
rates than non-KW practices (ﬁgure 1A). All results refer to
changes after adjusting for seasonal variation and the underlying
temporal trends. Following the introduction of KW health
checks (vertical line), a small increase of 0.4% in the CHD mor-
tality rate in the KW population was observed (95% CI −5.2%
to 6.3%; table 1). In non-KW practices, CHD mortality rates
decreased by 0.3% (95% CI −2.7% to 2.2%) over the same
period.
For stroke mortality, a high degree of month-to-month vari-
ability was observed, with an overall downward trend for both
groups, with higher rates in KW wave 1 practices (ﬁgure 1B).
Comparing periods before and after the introduction of KW
checks, stroke mortality increased by 6.7% (95% CI −2.6% to
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16.9%) in KW practices. The adjusted mortality rate in non-KW
practices showed no appreciable change (0.2%; 95% CI −6.7%
to 6.7%) during the same period.
CHD incident hospitalisation rates decreased by 1.1% (95%
CI −3.4% to 1.3%) in KW practices, comparing the periods
before and after the introduction of health checks (ﬁgure 1C).
In non-KW practices, no appreciable change in CHD incident
hospitalisation rates was found (−0.1%; 95% CI −1.8% to
1.7%) comparing the same two periods (table 1). Stroke incident
hospitalisations showed a decrease of 1.5% (95% CI −4.4% to
1.6%) in KW practices and no appreciable change (−0.1%; 95%
CI −1.5% to 1.3%) in non-KW practices (table 1). The inclusion
of the data series of non-KW practices did not alter results for
KW practices appreciably (table 1).
Prescribing
In KW and non-KW practices, prescription rates (expressed as
DDDs per 100 patients) for all drug classes increased over time,
although rates for antiplatelets showed only a small increase.
Prescription rates for statins were consistently higher in KW
than in non-KW practices (ﬁgure 2A), while rates for antihyper-
tensive drugs were similar (ﬁgure 2B). For antiplatelet prescrip-
tions, rates started to decline from 2009 onwards (ﬁgure 2C).
There was some degree of seasonality in rates, in particular for
statins and antihypertensive drugs.
Statin prescription rates showed a small increase of 0.4%
(95% CI −10.4% to 12.5%) in KW practices following the intro-
duction of health checks (table 1). In non-KW practices, com-
parison of the corresponding periods showed a decrease in the
statin prescription rate of 1.5% (95% CI −9.4% to 7.2%) relative
to the underlying trend. In KW practices, the antihypertensive
prescription rate decreased by 2.5% (95% CI −12.3% to 8.4%)
following the introduction of the KW intervention, whereas in
non-KW practices, a decrease of 1.6% (95% CI −7.1% to 4.3%)
was observed. The prescription rate for antiplatelets decreased
by 0.9% (95% CI −6.5% to 5.0%) in KW practices and by 2.4%
in non-KW practices (95% CI −10.1% to 6.0%).
Prescribing at practice level
We considered the possibility that the KW intervention might be
more effective in some NHS Boards than others, due to
board-level variations in the degree of engagement with the pro-
gramme by including interaction terms between health board
and the intervention (table 1). For statins, a negative association
was found between the intervention and prescription rates, sug-
gesting a decrease in prescription rates after the introduction of
KW. This decrease was modiﬁed by health board area, with
NHSGGC showing a larger decrease than the other two health
boards (−3.9% (95% CI −7.6% to −0.1%)). Prescription rates
for antihypertensive drugs declined at a higher rate in Lothian
than in the remaining two health board areas (−5.7%; 95% CI
−11.2% to 0.04%). Trends in antiplatelet prescription rates
were not altered by the introduction of the KW intervention
(ﬁgure 2C and table 1). In NHSGGC and Lothian, the interven-
tion was associated with an increase in rates of DDDs, whereas
in Lanarkshire, a relative decrease was observed. The GEE
models without the interaction terms had a smaller QIC value
than those with interactions, partly supporting our conclusions
that changes in prescription rates were not markedly modiﬁed
by health board location.
Online supplementary ﬁgure S3A–C shows results displayed
as forest plots.
DISCUSSION
Six years after the introduction of health checks in KW wave 1
practices, any effect of the intervention on trends in CHD and
stroke mortality, incident hospitalisations and prescription rates
Table 1 Modelled changes in mortality, hospitalisation and
prescriptions in KW and non-KW practices comparing
preintervention and postintervention periods
Intervention effect
(95% CI) p Value
Model
test
statistic
Percentage change in mortality
rates*
R2
CHD mortality (KW) 0.4 (−5.2 to 6.3) 0.89 57.9
CHD mortality (non-KW) −0.3 (−2.7 to 2.2) 0.83 79.4
CHD mortality (net effect) 0.4 (−5.1 to 6.3) 0.88 76.3
Stroke mortality (KW) 6.7 (−2.6 to 16.9) 0.16 45.6
Stroke mortality (non-KW) −0.2 (−6.7 to 6.7) 0.95 55.2
Stroke mortality (net effect) 6.9 (−2.2 to 16.9) 0.14 38.5
Percentage change in incident
hospitalisation rates*
R2
CHD hospitalisations (KW) −1.1 (−3.4 to 1.3) 0.37 79.5
CHD hospitalisations (non-KW) −0.05 (−1.8 to 1.7) 0.96 85.1
CHD hospitalisations (net
effect)
−1.0 (−3.2 to 1.3) 0.40 86.8
Stroke hospitalisations (KW) −1.5 (−4.4 to 1.6) 0.35 49.9
Stroke hospitalisations
(non-KW)
−0.1 (−1.5 to 1.3) 0.87 47.4
Stroke hospitalisations (net
effect)
−1.4 (−4.4 to 1.6) 0.35 39.6
Percentage change in rates of
DDDs prescribed* (aggregate
level; time series)
R2
Statins (KW) 0.4 (−10.4 to 12.5) 0.94 98.9
Statins (non-KW) −1.5 (−9.4 to 7.2) 0.73 99.3
Statins (net effect) 2.2 (−2.7 to 7.36) 0.39 99.9
Antihypertensives (KW) −2.5 (−12.3 to 8.4) 0.64 95.7
Antihypertensives (non-KW) −1.6 (−7.1 to 4.3) 0.60 97.6
Antihypertensives (net effect) −0.3 (−4.5 to 4.0) 0.88 99.5
Antiplatelets (KW) −0.9 (−6.5 to 5.0) 0.76 78.6
Antiplatelets (non-KW) −2.4 (−10.1 to 6.0) 0.56 84.1
Antiplatelets (net effect) 2.0 (−0.86 to 5.0) 0.17 97.6
Percentage change in rates of
DDDs prescribed* (practice level;
GEE)†
QIC
Statins (without interaction) −2.5 (−5.2 to 0.4) 0.09 314.24
Statins (GGC) −3.9 (−7.6 to −0.1) 0.04 335.77
Statins (Lanarkshire) −2.2 (−5.7 to 1.5) 0.25 335.77
Statins (Lothian) −1.3 (−8.6 to 6.5) 0.73 335.77
Antihypertensives (without
interaction)
−1.2 (−4.0 to 1.6) 0.39 475.18
Antihypertensives (GGC) −1.03 (−5.9 to 4.1) 0.68 496.8
Antihypertensives (Lanarkshire) 0.5 (−3.0 to 4.1) 0.79 496.8
Antihypertensives (Lothian) −5.7 (−11.2 to 0.04) 0.05 496.8
Antiplatelets (without
interaction)
0.4 (−2.6 to 3.4) 0.82 440.81
Antiplatelets (GGC) 1.8 (−1.8 to 5.6) 0.33 461.52
Antiplatelets (Lanarkshire) −0.8 (−4.6 to 3.2) 0.68 461.52
Antiplatelets (Lothian) 1.5 (−4.2 to 7.5) 0.62 461.52
*Percentage change in the mean level of outcome after KW was implemented in all
participating practices (from September 2010) compared with the mean level of
outcome before KW was implemented in any practice (prior to October 2006).
†After adjustment for underlying secular trend and seasonal variation excluding NHS
Tayside.
CHD, coronary heart disease; DDD, defined daily dose; GEE, generalised estimating
equation; GGC, Greater Glasgow and Clyde; KW, Keep Well; NHS, National Health
Service.
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was likely to be very small. Once the seasonal pattern and
strong downward temporal trend are taken into account, our
results are consistent with both increases and decreases in mor-
tality and hospitalisation following the intervention, but based
on the CIs, we can fairly reliably exclude reductions of more
than 1–2% in hospitalisations and of more than 3–6% in mor-
tality (because of the greater uncertainty due to the smaller
number of deaths).
Comparing the periods before and after the start of KW
health checks, we found small relative declines in prescribing of
statins, antihypertensive and antiplatelet drugs. These declines
were observed in KWand non-KW practices.
Strengths and limitations
The data have complete national coverage and are likely to
accurately estimate the incidence of CVD and CVD-related
Figure 1 (A–D) Mortality and incident hospitalisation rates (coronary heart disease (CHD) and stroke) in Keep Well (black line) and non-Keep Well
(grey line) practices (vertical line indicates introduction of Keep Well intervention).
Figure 2 (A–C) Mean rates of deﬁned daily doses (DDDs) prescribed by drug class in Keep Well (black line) and non-Keep Well (grey line)
practices (vertical line indicates introduction of Keep Well intervention).
4 Geue C, et al. J Epidemiol Community Health 2016;0:1–6. doi:10.1136/jech-2015-206926
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prescribing in Scotland with a low likelihood of missing cases
or misclassiﬁcation. The ARIMA models were supported by
relatively long time series available both before and after the
intervention and accounted for random variation, temporal
trends and seasonality. The health outcomes were clearly linked
to the original deﬁned purpose of ‘wave 1’ of KW and allowed
the theory to be evaluated at different points after
implementation.
We limited the analysis to ‘wave 1’ because subsequent waves
had a less consistent focus on CVD, operated in more diverse
settings where consistent monitoring data were not always avail-
able, and had a shorter duration of follow-up.
We were not able to access individual-level data nationally
because information sharing was not agreed with general practi-
tioners (GPs). This meant that we had to deﬁne the eligible
population at practice level (for prescriptions) or for speciﬁc age
groups within practices (for hospitalisations and mortality) and
no adjustments for patient characteristics was possible.
However, any changes in practice conﬁguration (age structure,
sex and deprivation) would be similar in KW and in non-KW
practices. Since the analyses compare changes within KW prac-
tices and changes within non-KW practices, it is unlikely that
aggregation would affect results. Furthermore, aggregation
meant a reduction in the power of the study to detect any
impact of the intervention by misclassifying some untreated
individuals as treated. Similarly, it is likely that the comparison
group (the rest of the Scottish population) included some
people who received a health check as part of subsequent waves
of KW. The effect of both of these factors would be to dilute
the measured impact of KW, creating a bias towards a null
result. However, KW recipients other than wave 1 formed a very
small proportion of the overall Scottish population, so the
impact of this bias is likely to be small. It is also important to
recognise that analyses at individual level (as performed in some
local studies) provide information only on efﬁcacy (ie, potential
beneﬁts for those who actually received checks) rather than on
real-life population impact. Although aggregate mortality and
hospitalisation data were used in our analyses, this approach is
likely to give a more realistic estimate of the ‘real-life’ effective-
ness of the programme.
Information was available on the approximate dates on which
each general practice started health checks as part of KW wave
1 but not on the speed or intensity with which the intervention
was implemented. If some practices implemented the pro-
gramme in a less vigorous way, this may have diluted the impact
of KW. Our analyses of prescription rates including interaction
terms between health board and the intervention variable
attempted to account for overall variations between practices in
different health boards.
Clinical guidelines ﬁrst published in 2007 recommended that
CVD risk should be assessed in all individuals aged 40 years and
above at least every 5 years, although this was based on low-
quality evidence.20 Guidelines also recommend (for those at
high risk) prescription of antiplatelet therapy and statins, and
antihypertensive therapy for those with hypertension.21–23
However, the effectiveness of CVD screening programmes has
been disputed for some time,24 25 with the latest Cochrane
reviews concluding that there is evidence for a reduction in risk
factors but not mortality or morbidity and that universal health
checks should therefore be abandoned.26 27
Evaluation of health checks in England have found that, on
average, there is no evidence of an increased identiﬁcation of
undiagnosed disease28 but some evidence of decreased CVD
risk.29 30 A recent study reported an increased detection of
hypercholesterolaemia but no increase in detection of obesity,
smoking and hypertension.31 However, these studies do not
account for secular trends (eg, declining smoking rates) and one
is subject to a number of important biases including regression
to the mean and selection bias.32
Although these results are somewhat imprecise, they make it
very unlikely that the implementation of the ﬁrst wave of KW
health checks in Scotland was associated with substantial or
important changes in CVD outcomes or prescribing. It is pos-
sible though that the overall level of health check coverage was
not sufﬁcient to produce a measurable effect or that participants
did not receive all the interventions that were originally
planned. This, however, reﬂects the nature of an effectiveness
study (rather than efﬁcacy) and is perhaps a more realistic assess-
ment of the real-world impact. It is possible that while the indi-
vidual components of the KW check (drug therapy, lifestyle
advice, etc) are effective in trial situations, other factors includ-
ing the challenges of programme delivery and the individual
situations of people in deprived circumstances mean that their
real-life effectiveness is much less. This may also include varia-
tions in care delivered by different healthcare professionals; that
is, nurses, GPs and other staff.
Our analyses include a 6 years follow-up, but it is possible
that clear beneﬁts might only emerge later because of the
length of time required for primary prevention to reduce risk
factors and decrease morbidity and mortality at population
level. Given the change in prescription rates was found to be
small, it seems unlikely that mortality and hospitalisation rates
would change.
CONCLUSIONS
Effective interventions are available for primary CVD preven-
tion. However, our ﬁndings are consistent with systematic
reviews suggesting that delivering these interventions in a sys-
tematic population wide way may not be effective. The KW
approach (like the English Health Check programme) is essen-
tially a screening programme, and more rigorous evidence of
effectiveness is required before it is adopted. Our interrupted
time series approach could be criticised as a weaker design than
cluster randomisation or stepped wedge approaches. We suggest
that for large-scale population interventions, randomised
approaches are more feasible than currently assumed by policy-
makers, and we think they should be more widely used.
What is already known on this subject
▸ Effective interventions are available to reduce cardiovascular
risk. In theory, these could prevent cardiovascular disease
(CVD) in asymptomatic individuals and narrow existing
socioeconomic inequalities in health.
▸ Health check programmes have been implemented to
speciﬁcally target those at high risk of CVD, but there is
controversy about whether these are likely to be effective at
the population level and about whether a screening
approach is justiﬁed.
▸ A key early aim of the Scottish Keep Well programme was
to narrow socioeconomic inequalities in CVD by targeting
individuals living in deprived areas, screening for CVD
risk factors and then providing drug therapies (eg, statins
and antihypertensives) and lifestyle advice for those at
high risk.
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What this study adds
Our study suggests that, after accounting for seasonal and
secular trends, the effect of the Keep Well intervention on CVD
mortality and incident hospitalisation was unlikely to be
substantial.
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